
Clinical Updatesdrug resistanceBCL2 inhibitor
Dynamic Genetic and Nongenetic RAS-Pathway Activation Drives Resistance to FLT3 and BCL2 Inhibitor Therapy in AML
By MedXY|Sep 24, 2026
This review synthesizes cutting-edge findings on how genetic and nongenetic RAS-pathway activation mediates resistance to combined FLT3 and BCL2 inhibition in acute myeloid leukemia, highlighting implications for treatment strategies and bi